Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Osmotica Pharmaceuticals plc today announced the pricing of its initial public offering of 6,650,000 ordinary shares at a public offering price of $7.00 per share.
Aclaris Therapeutics, Inc. today announced the pricing of its underwritten public offering of 8,645,000 shares of its common stock at a price to the public of $10.75 per share.
French company Innate Pharma and UK-based AstraZeneca have had a research collaboration deal in place since 2015. The two companies announced a new multi-term deal to build on that collaboration.
Two years after forging a partnership to collaborate on microbiome targets for gastrointestinal disorders, France-based Enterome SA and Takeda Pharmaceuticals have entered into a second agreement. This time with a specific focus on Crohn’s disease.
MDxHealth SA (Euronext Brussels: MDXH) (“MDxHealth” or the “Company”), announced that it received on October 12, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the “Belgian Transparency Act”).
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Shares of Indiana-based Endocyte have shot up more than 50 percent in pre-market trading after Swiss pharma giant Novartis announced it was acquiring the company for $2.1 billion in cash. The deal will allow the company to expand its radiopharmaceuticals business.
Discovery Life Sciences, a leading research biobank located in Los Osos, California, recently got much, much bigger via a four-company merger. Ann Dover, Discovery’s founder, president and CEO, took time to speak with BioSpace about the merger and the new identity of the company.
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
The U.S. Department of Justice has given preliminary approval for CVS’ $69 billion acquisition of Aetna after Aetna divested its Medicare Part D business.